The Research Centre at the University of Wolverhampton is leading the way in identifying the genetic causes of brain tumours and the treatments to deal with them.
Around 8,500 people will develop a brain tumour in the UK this year. Many of these will be malignant and respond poorly to therapy. Spending on brain tumour research is significantly lower than on many other types of cancer and this undoubtedly has hindered the development of new, effective treatments.
Professor Tracy Warr, leading the Neuro-Oncology Research Centre at the University of Wolverhampton, said:
“Brain tumours grow very quickly and are very resistant to conventional therapies. We have made some exciting progress with our laboratory tests but extra research and funding is needed to develop them further.
“Funding for research in the UK is desperately needed. Unless we address the huge challenges faced by young research scientists who want to pursue a career in brain tumour research, we risk losing them to overseas research institutes or to other specialisms.”
Professor Warr’s team is investigating new drugs that target abnormal metabolism, especially energy production. Brain tumours produce the energy that they need to grow in a different way to normal brain cells so these drugs could kill brain tumour cells whilst sparing normal brain cells and reducing side effects for patients. “We are making tremendous progress in the laboratory and we believe that our research will make a real difference to patients suffering from this devastating disease” said Professor Warr.